Fantasista Co., Ltd.
1783・Standard Market・Real Estate
Healthcare Business
An early-stage business engaged in the distribution and sale of 5-ALA-containing supplements
| Period | Current | Previous | Change |
|---|---|---|---|
| Revenue (H1 FY2026, cumulative) | ¥62 million | ¥72 million (H1 FY2025, cumulative) | ↓ |
| Segment loss (H1 FY2026, cumulative) | -¥10 million | -¥6 million (H1 FY2025, cumulative) | ↓ |
| Revenue (full year: FY2025) | ¥138 million | — | — |
| Segment loss (full year: FY2025) | -¥1 million | — | — |
Business Details
A business centered on the distribution and sale of products containing 5-ALA (5-aminolevulinic acid). In addition to existing 5-ALA products, the company has newly developed three supplements targeting men, children, and pets, and is pursuing expansion into new customer segments. As of the H1 FY2026 (ending March 2026) period, sales of the men's and pet supplements have already commenced, while sales of the remaining children's supplement are scheduled to begin shortly. The business is currently in a phase of upfront investment, including building sales promotion frameworks for the new product lineup.
Recent Overview
Two new products launched, but losses widened due to upfront investment
During H1 FY2026 (ending March 2026) (October 2025 to March 2026), the company began sales of men's and pet supplements. However, due to being in a phase of upfront investment such as building sales promotion frameworks for the new product lineup, revenue was ¥62 million (down 12.9% year-on-year) and the segment loss widened to ¥10 million (versus a loss of ¥6 million in the same period a year earlier). Sales of the children's supplement are scheduled to begin shortly.
Key Products
Growth Drivers
- Expansion into new customer segments through three new products targeting men, children, and pets
- Recovery and retention of trust among existing customers through strengthened quality control and management of 5-ALA raw materials
- Increased brand recognition through sales promotion measures implemented for the new product lineup
Risks
- Risk that the decline in consumer trust in health foods and supplements, triggered by the March 2024 Beni-koji related issue, continues
- Risk that segment losses expand in the short term due to upfront investment for new product rollout (segment loss widened to ¥10 million in H1 FY2026)
- Risk that the launch of the new children's product is delayed or that market penetration falls short of expectations
- Risk of increased costs related to procurement and quality control of raw materials (5-ALA active ingredient)
- Risk that revenue continues to trend downward year-on-year, and that revenue recovery takes time until the effects of new products materialize
Last updated: December 22, 2025